International law firm Brown Rudnick LLP advised on the intellectual property aspects of the initial public offering of Aerovate Therapeutics Inc. Raising more than $120 million, Aerovate saw its shares skyrocket on its first day of trading on the Nasdaq Exchange. Brown Rudnick has advised and continues to advise the company on intellectual property, including on the IPO.

Having had one of the most successful initial trading days in recent memory, Aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's initial focus is on advancing AV-101, its dry powder inhaled formulation of the drug imatinib for the treatment of pulmonary arterial hypertension, or PAH.

The Brown Rudnick deal team includes Intellectual Property specialists Adam Schoen and Daniel Palmer. Michael Cohen of Brown Rudnick’s Corporate and Capital Markets Practice Groups also counseled Aerovate in the lead-up to its IPO. Brown Rudnick’s Global Life Sciences Group consists of a team of lawyers dedicated to the life sciences industry. The team includes former biotech and healthcare executives and scientists who have a deep understanding of the life sciences landscape.